PMD19 A CRITICAL REVIEW OF HEALTH-RELATED PRODUCTIVITY MEASURES  by Prasad, M et al.
535Abstracts
PMD17
ASSESSMENT OF QUALITY OF LIFE IN
CHILDREN: METHOLOGICAL AND
CONCEPTUAL ISSUES
Matza LS1, Swensen A2, Flood E1, Secnik K2
1MEDTAP International, Bethesda, MD, USA; 2Eli Lilly and
Company, Indianapolis, IN, USA
OBJECTIVES: Researchers are gradually becoming more
aware of the unique challenges of assessing health out-
comes among children, including health-related quality of
life (HRQL). Like adults, children experience impacts of
illness and treatment beyond purely medical effects. More
pediatric HRQL research is necessary to identify these
broader outcomes and provide a thorough understanding
of children’s health status. Thus, the purpose of this 
presentation is to review recent pediatric pharmaceutical
regulatory developments and discuss methodological 
and conceptual issues relating to the assessment of chil-
dren’s HRQL. METHODS: Computerized literature
searches were conducted in MEDLINE, HealthSTAR, 
and PSYCH-INFO from 1990 to 2002. Internet searches 
were conducted to identify regulatory developments. To
empirically examine the HRQL impact of a childhood
psychiatric disorder, baseline data from a clinical trial of
children with ADHD were compared with normative
data. RESULTS: Over 200 abstracts were located, and 
80 relevant articles were selected for detailed review.
Commonly used instruments included the Child Health
Questionnaire. Several methodological issues were iden-
tiﬁed, including when to use parents as proxy respondents
and the age at which children can recognize and report
their HRQL. Consideration should be given to the
content, language, presentation style, and response
choices in order to ensure that child-report measures are
age-appropriate. One conceptual issue involves the inter-
action of children’s HRQL and social contexts, including
family and peer systems. The empirical analyses suggested
that ADHD, one example of a psychiatric disorder, has 
a serious impact on children’s HRQL (p < 0.0001). 
CONCLUSIONS: There are numerous methodological
and conceptual issues unique to research on HRQL in
children. Based on brief empirical analyses, it is recom-
mended that future research examine the impact of 
psychiatric disorders, as well as medical conditions, on
children’s HRQL. Finally, we advocate additional regula-
tion to encourage assessment of pediatric health outcomes
among children as an integral part of drug development.
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THE INTERNATIONAL HEALTH-RELATED
QUALITY OF LIFE OUTCOMES DATABASE
(IQOD) PROGRAMME—WHQ AND PGWBI
DATABASES: REFERENCES VALUES FOR CROSS-
CULTURAL COMPARISONS
Lobo-Luppi L, Mouly M
IQOD Group, Mapi Research Institute, Lyon, France
With the increased number of multinational clinical trials
and epidemiological studies using Patient-Reported 
Outcomes (PRO), the need of cross-cultural reference
values for analysis and interpretation has arisen. 
OBJECTIVE: The International Health-related Quality 
of Life Outcomes Database (IQOD) Programme aims at
creating scores and standardizing analysis and interpre-
tation for health-related quality of life questionnaires.
METHODS: Data were collected from multiple clinical
trials and epidemiological studies conducted worldwide.
The IQOD Programme Phase I involves the Women’s
Health Questionnaire (WHQ), the Psychological General
Well-Being Index (PGWBI), and the Minnesota Living
with Heart Failure Questionnaire (MLHF). These instru-
ments represent three types of PRO: generic, condition,
and disease speciﬁc instruments, selected for their lin-
guistic adaptation into several languages, their reliability
and validity, and their extensive use. Descriptions of 
population, analysis and interpretation provide reference
values in different population groups and per country.
RESULTS: Data collection and speciﬁcation include the
elaboration of the merging rules in order to incorporate
the results of multiple studies while building the 
databases. IQOD-WHQ collected data among 9023
women (mean age: 52 years), using the 37-item version
of the WHQ, were analysed and interpreted. Pre, peri and
post-menopausal women reference values have been
established for 6 languages, 10 European countries and
USA. WHQ’s scoring has been reviewed with the author
and a 23-item short-form WHQ has been developed.
IQOD-PGWBI database includes data of 11 286 patients
(mean age: 46 years) living in 19 countries, speaking 15
languages with symptomatic GERD, HTA, chronic 
constipation, colorectal cancer, digestive problems and
several co-morbidities. IQOD-MLHF data collection is
being ﬁnalized. CONCLUSION: IQOD-WHQ and
IQOD-PGWBI databases analysis provides reference
values for comparison of PRO data across populations
(countries and languages), cultures and condition sever-
ity. Ongoing and future work in IQOD focus on creating
similar reference values for IQOD-MLHF and other
PRO.
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OBJECTIVES: Health impairment often leads to work
impairment in the form of both absenteeism and presen-
teeism, which is reduced productivity at work. To date,
few instruments are available to measure this impact. The
objective of this study was to review and evaluate instru-
ments designed to measure health-related productivity at
work. METHODS: A literature search was conducted
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using ABI Info, EconLit, PsychInfo, MEDLINE, 
CANCERLIT, AIDSLINE, HealthStar; databases were
searched from 1990–2001. Articles identiﬁed comprised
productivity measured by subjective (self-report ques-
tionnaires) and objective (computer-based tracking
systems) techniques; subjective instruments included both
generic and disease-speciﬁc measures. Identiﬁed instru-
ments were evaluated on psychometric properties, 
generalizability to different populations, and administra-
tor/respondent burden. RESULTS: Five generic subjective
measures were identiﬁed—the Endicott Work Produc-
tivity Scale; Health and Labor Questionnaire; Health and
Work Questionnaire; Work Limitations Questionnaire;
and the Work Productivity and Activity Impairment
Questionnaire (WPAI)—that could theoretically be used
in any working population. All subjective instruments
showed adequate to good reliability. However, these
instruments were usually validated against other subjec-
tive measures (such as health-related quality of life), as a
uniform measure of “productivity” does not exist. The
WPAI was the most frequently used instrument and has
also been modiﬁed to measure productivity reductions
associated with speciﬁc diseases (e.g., allergic rhinitis,
gastro-esophageal reﬂux disease). Objective assessments
have been carried out to measure employee productivity
for tasks where individual output could be quantiﬁed
(e.g., claims processed, telephone inquiries handled). To
avoid respondent bias, these studies utilized computer-
based tracking systems to determine productivity reduc-
tion attributable to illness. CONCLUSIONS: Subjective
and objective productivity assessments offer different
beneﬁts: while subjective instruments can be used in 
populations with different illnesses and/or jobs, objective
measures minimize respondent bias but are associated
with restricted generalizability and are burdensome to
carry out in practice.
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OBJECTIVE: Allogeneic stem cell transplantations 
(SCT) for leukaemias are known to be one of the most
expensive medical procedures. In the Netherlands, a 
few licensed hospitals perform allogeneic SCT. However,
the budgets they receive are not sufﬁcient (for instance
due to the application of donor lymphocyte infusions).
We calculated the direct medical costs of patients 
who underwent allogeneic SCT to support a budget 
revision. METHODS: Costs of HLA-identical sibling
bone marrow transplantation (BMT), bone marrow
transplantation from a Matched Unrelated Donor (MUD)
and peripheral blood stem cell transplantation (PBSCT)
were identiﬁed. Costs were determined by two comple-
mentary methods. First, medical consumption for these
patients was determined and multiplied by the unit costs
of each of the items. Second, a structural program for
allogeneic transplantations brings along costs that are not
expressed in the registration of the medical consumption
of patients (e.g. HLA-typing and selection of the unre-
lated donor). The costs of these items were identiﬁed in
cooperation with the ﬁnancial departments of the hospi-
tals, and by expert opinion. RESULTS: The average costs
per transplanted patient were €98,334 (BMT), €151,754
(MUD), and €98,977 (PBSCT) for a follow-up period of
2 years. This includes the costs of hospitalizations,
medical procedures, medication, donor identiﬁcation and
the costs of patients who were not transplanted after they
had been planned to receive an allograft. The majority of
costs were made prior to and during hospitalization for
graft infusion. In MUD transplantation the costs of
ﬁnding a suitable donor comprise nearly one third of total
costs. CONCLUSION: This cost analysis gives a proper
indication of the costs associated with performing differ-
ent types of allogeneic SCTs and maintaining a structural
transplantation program in the Netherlands. The results
of this analysis will be used in determining a new budget
for allogeneic SCTs in the Netherlands.
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OBJECTIVES: The objective of this health technology
assessment commissioned by the German Agency for
Health Technology Assessment at DIMDI/German
Federal Ministry of Health was to conduct a systematic
review of the cost-effectiveness of new cervical cancer
screening techniques, and to perform a decision-analysis
in the context of the German health care system.
METHODS: A systematic literature review and assess-
ment on quality/transferability of data was performed
using instruments developed by the German Scientiﬁc
